Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Free Cash Flow: 2022-2024

Historic Free Cash Flow for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to -$50.8 million.

  • Orchestra BioMed Holdings' Free Cash Flow fell 7.93% to -$14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year decrease of 26.19%. This contributed to the annual value of -$50.8 million for FY2024, which is 10.05% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Free Cash Flow stood at -$50.8 million for FY2024, which was down 10.05% from -$46.2 million recorded in FY2023.
  • In the past 5 years, Orchestra BioMed Holdings' Free Cash Flow ranged from a high of -$29.9 million in FY2022 and a low of -$50.8 million during FY2024.
  • For the 3-year period, Orchestra BioMed Holdings' Free Cash Flow averaged around -$42.3 million, with its median value being -$46.2 million (2023).
  • Data for Orchestra BioMed Holdings' Free Cash Flow shows a maximum YoY crashed of 54.64% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Orchestra BioMed Holdings' Free Cash Flow stood at -$29.9 million in 2022, then slumped by 54.64% to -$46.2 million in 2023, then declined by 10.05% to -$50.8 million in 2024.